Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | President | September 09, 2020 | September 11, 2020 |
| Acorda Therapeutics, Inc.ACOR · Entity 111987 | Director | June 02, 2021 | June 04, 2021 |
| BCLS Acquisition Corp.BLSA · Entity 145747 | Director | October 22, 2020 | October 22, 2020 |
| CITY THERAPEUTICS, INC.CTY · Entity 184066 | Director | October 15, 2026 | October 16, 2026 |
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Director | June 22, 2026 | June 23, 2026 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date September 09, 2020 · Filed September 11, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,412 |
Reported balance
After 2020-07-16 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2020-07-16 · Gift · Acquired 3,176 · Balance 65,412 F1: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person. |
| Common StockSEC Table I · non-derivative | Direct | 114,873 |
Reported balance
After 2020-09-09 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2020-09-09 · Exercise / conversion · Acquired 44,530 · Balance 114,873 F2: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020. |
| Common StockSEC Table I · non-derivative | Direct | 100,798 |
Reported balance
After 2020-09-09 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2020-09-09 · Sale · Disposed 14,075 · Balance 100,798 F2: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020. F3: Sale prices ranged from $122.00 to $123.00. |
| Common StockSEC Table I · non-derivative | Direct | 73,689 |
Reported balance
After 2020-09-09 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2020-09-09 · Sale · Disposed 27,109 · Balance 73,689 F2: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020. F4: Sale prices ranged from $123.01 to $124.00. |
| Common StockSEC Table I · non-derivative | Direct | 70,343 |
Reported balance
After 2020-09-09 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2020-09-09 · Sale · Disposed 3,346 · Balance 70,343 F2: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020. F5: Sale prices ranged from $124.03 to $124.87. |
| Common StockSEC Table I · non-derivative | Indirectby Dependent | 155 |
Reported balance
After 2020-07-16 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2020-07-16 · Gift · Acquired 155 · Balance 155 F1: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 3,331 |
Reported balance
After 2020-07-16 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2020-07-16 · Gift · Disposed 155 · Balance 3,331 F1: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 3,176 |
Reported balance
After 2020-07-16 transaction · row 8
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 8 · 2020-07-16 · Gift · Disposed 155 · Balance 3,176 F1: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 0 |
Reported balance
After 2020-07-16 transaction · row 9
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 9 · 2020-07-16 · Gift · Disposed 3,176 · Balance 0 F1: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.14 · Expires 2020-12-08 | Direct | 0 |
Reported balance
After 2020-09-09 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-09-09 · Exercise / conversion · Disposed 44,530 · Balance 0 F2: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020. F7: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 3,003 |
Reported balance
Holding disclosure · report date 2020-09-09 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 3,003 F6: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person.
F2: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020.
F3: Sale prices ranged from $122.00 to $123.00.
F4: Sale prices ranged from $123.01 to $124.00.
F5: Sale prices ranged from $124.03 to $124.87.
F6: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
F7: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.
Acorda Therapeutics, Inc.
Report date June 02, 2021 · Filed June 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.75 · Expires 2031-06-02 | Direct | 10,000 |
Reported balance
After 2021-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-02 · Grant · Acquired 10,000 · Balance 10,000 F1: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 2, 2021, with the first quarterly installment vesting on September 2, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 2, 2021, with the first quarterly installment vesting on September 2, 2021.
BCLS Acquisition Corp.
Report date October 22, 2020 · Filed October 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-10-22 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249284) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249284) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
CITY THERAPEUTICS, INC.
Report date October 15, 2026 · Filed October 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.92 · Expires 2034-09-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-15 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares underlying this option vest in 48 equal monthly installments following September 29, 2024, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in 48 equal monthly installments following September 29, 2024, subject to the Reporting Person's continued service on each such vesting date.
Dyne Therapeutics, Inc.
Report date June 22, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.87 · Expires 2036-06-21 | Direct | 57,463 |
Reported balance
After 2026-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 57,463 · Balance 57,463 F1: The option was granted on June 22, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments through June 22, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 22, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments through June 22, 2029.
Karyopharm Therapeutics Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,415 |
Reported balance
After 2026-05-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 15,508 · Balance 16,415 F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event. F2: Amounts reported in this Form 4 reflect the one-for fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event.
F2: Amounts reported in this Form 4 reflect the one-for fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sage Therapeutics, Inc.
Report date July 31, 2025 · Filed July 31, 2025
Section 16 reporting ended · disclosed 2025-07-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2025-07-31 · Other · Disposed 46,940 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2025-07-31 · Disposition to issuer · Disposed 53,229 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.97 · Expires 2035-01-16 | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-31 · Disposition to issuer · Disposed 174,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes.
F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025.
F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2020 Filed May 7, 2020 20:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 22,265 | $0.00 Strike: $9.14 | $0.00 |
DisclosureSEC source: 0001735276-20-000060 · edgardoc.xml · derivative · entry 5 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,795 Underlying: Common Stock · 22,265 shares Expires 2020-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 22,265 options exercised and sold by the reporting person were due to expire on December 8, 2020. F4 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| May 06, 2020 Filed May 7, 2020 20:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 22,265 | $149.99 | $3,339,527.35 |
DisclosureSEC source: 0001735276-20-000060 · edgardoc.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,236 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 22,265 options exercised and sold by the reporting person were due to expire on December 8, 2020. Read SEC document |
| May 06, 2020 Filed May 7, 2020 20:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 22,265 | $9.14 | $203,502.10 |
DisclosureSEC source: 0001735276-20-000060 · edgardoc.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 22,265 options exercised and sold by the reporting person were due to expire on December 8, 2020. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 64 | $106.65 | $6,825.60 |
DisclosureSEC source: 0001735276-20-000049 · edgardoc.xml · nonDerivative · entry 3 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,236 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 1,599 | $104.75 | $167,495.25 |
DisclosureSEC source: 0001735276-20-000049 · edgardoc.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,300 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 5,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-20-000049 · edgardoc.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,899 F1 · kind: On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. This PSU award vests in three equal installments upon the later of one year from the date of grant and the achievement of each of three specific clinical development, regulatory or commercial events. One third of the shares subject to release under the PSU award vested upon the filing by the Company of its fourth NDA with the FDA, as determined by the compensation committee of the Company effective April 7, 2020. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 21:35 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 3,030 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001209191-20-019709 · doc4.xml · derivative · entry 2 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,030 shares Expires 2021-04-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option representing a right to purchase a specified number of shares vested as to 25% of the shares on April 14, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 21:35 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 3,030 | $0.03 | $99.99 |
DisclosureSEC source: 0001209191-20-019709 · doc4.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 29,925 | $0.00 Strike: $118.05 | $0.00 |
DisclosureSEC source: 0001735276-20-000029 · edgardoc.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,925 Underlying: Common Stock · 29,925 shares Expires 2030-02-25 F1 · shares: Represents the time-vested stock option portion of the reporting person's Annual Equity Award for 2019. The reporting person also received 16,519 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the performance stock units vest. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 21:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2017 (right to buy) · Derivative | 9,999 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-19-000119 · edgardoc.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,998 Underlying: Common Stock · 9,999 shares Expires 2028-03-01 F1 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the second performance criterion was met and the option vested as to the second one third of the shares as of December 23, 2019. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2017 (right to buy) · Derivative | 9,999 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-19-000110 · edgardoc.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,999 Underlying: Common Stock · 9,999 shares Expires 2028-03-01 F1 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the first performance criterion was met on November 22, 2019 and the option vested as to the first one third of the shares as of such date. Read SEC document |
| October 23, 2019 Filed Oct 24, 2019 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 5,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000094 · edgardoc.xml · nonDerivative · entry 4 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 3,486 F2 · kind: These shares were distributed in October 2019 to the reporting person from the "Barry E. Greene Qualified Annuity Interest Trust" (GRAT). F3 · ownership.nature: Represents remaining shares held by the "Barry E. Greene Qualified Annuity Interest Trust" (GRAT), of which Barry E. Greene is the sole Trustee Read SEC document |
| October 23, 2019 Filed Oct 24, 2019 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 5,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000094 · edgardoc.xml · nonDerivative · entry 3 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,482 F2 · kind: These shares were distributed in October 2019 to the reporting person from the "Barry E. Greene Qualified Annuity Interest Trust" (GRAT). Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 58,913 | $0.00 Strike: $16.43 | $0.00 |
DisclosureSEC source: 0001735276-19-000094 · edgardoc.xml · derivative · entry 6 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,913 shares Expires 2019-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 14, 2019. The 58,913 options exercised and sold by the reporting person were due to expire on December 9, 2019. F5 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 58,913 | $89.99 | $5,301,580.87 |
DisclosureSEC source: 0001735276-19-000094 · edgardoc.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,938 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 14, 2019. The 58,913 options exercised and sold by the reporting person were due to expire on December 9, 2019. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 58,913 | $16.43 | $967,940.59 |
DisclosureSEC source: 0001735276-19-000094 · edgardoc.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 14, 2019. The 58,913 options exercised and sold by the reporting person were due to expire on December 9, 2019. Read SEC document |
| August 06, 2019 Filed Aug 7, 2019 20:16 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-19-000084 · edgardoc.xml · derivative · entry 5 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F4 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option vested upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the fourth performance criterion was met effective as of August 6, 2019 and the option vested as to the final one-quarter of the shares as of such date. Read SEC document |
| August 06, 2019 Filed Aug 7, 2019 20:16 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2015 (right to buy) · Derivative | 10,000 | $88.95 Strike: $88.95 | $889,500.00 |
DisclosureSEC source: 0001735276-19-000084 · edgardoc.xml · derivative · entry 4 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 10,000 shares Expires 2025-12-18 F3 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option vested upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the fourth performance criterion was met effective as of August 6, 2019 and the option vested as to the final one-quarter of the shares as of such date. Read SEC document |
| July 11, 2019 Filed Aug 7, 2019 20:16 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 46 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000084 · edgardoc.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 3,003 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 07:52 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantNon-Employee Stock Option · Derivative | 15,000 | $0.00 Strike: $7.54 | $0.00 |
DisclosureSEC source: 0001209191-19-038362 · doc4.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 19, 2019, with the first quarterly installment vesting on September 19, 2019. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 12:57 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001209191-19-035376 · doc4.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on June 6, 2020, provided that the reporting person continues to serve as a director of the issuer through such date. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-19-000046 · edgardoc.xml · derivative · entry 5 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F3 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. On June 6, 2019, the compensation committee of the Company determined the third performance criterion had been met on June 5, 2019 and the option vested as to one-quarter of the shares as of such date. Read SEC document |
| April 09, 2019 Filed Jun 7, 2019 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 52 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000046 · edgardoc.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 2,957 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 23:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 32,500 | $0.00 Strike: $85.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000034 · edgardoc.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2029-02-27 F1 · shares: Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2018. The reporting person also received 16,250 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| October 18, 2018 Filed Jun 7, 2019 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 21 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000046 · edgardoc.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 2,905 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:54 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-18-000071 · edgardoc.xml · derivative · entry 2 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F2 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:54 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2015 (right to buy) · Derivative | 10,000 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-18-000071 · edgardoc.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the third performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 20:15 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2015 (right to buy) · Derivative | 10,000 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-18-000061 · edgardoc.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee. Effective August 21, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 23:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Based Stock Option 2014 (right to buy) · Derivative | 15,875 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001325812-18-000031 · primary_doc.xml · derivative · entry 7 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,625 Underlying: Common Stock · 15,875 shares Expires 2024-12-17 F4 · kind: On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option vested as to the final third of the award Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 23:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Based Stock Option 2013 (right to buy) · Derivative | 15,000 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001325812-18-000031 · primary_doc.xml · derivative · entry 6 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 15,000 shares Expires 2023-12-18 F3 · kind: On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option will vest as to the final third of the award. Read SEC document |
| July 31, 2018 Filed Aug 14, 2018 23:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GiftCommon Stock | 9,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001325812-18-000031 · primary_doc.xml · nonDerivative · entry 5 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 9,030 F2 · ownership.nature: The 9,030 shares were previously reported as directly beneficially owned. On 7/31/2018, the shares were contributed to the "Barry E. Greene Qualified Annuity Interest Trust" (GRAT). Barry E. Greene is the sole trustee. Read SEC document |
| July 31, 2018 Filed Aug 14, 2018 23:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GiftCommon Stock | 9,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001325812-18-000031 · primary_doc.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,938 Read SEC document |
| July 10, 2018 Filed Aug 14, 2018 23:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 29 | $0.00 | $0.00 |
DisclosureSEC source: 0001325812-18-000031 · primary_doc.xml · nonDerivative · entry 4 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 2,884 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 07:42 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantNon-Employee Stock Option · Derivative | 15,000 | $0.00 Strike: $28.15 | $0.00 |
DisclosureSEC source: 0001209191-18-039989 · doc4.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-27 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 27, 2018, with the first quarterly installment vesting on September 27, 2018. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:15 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001209191-18-038757 · doc4.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2028-06-18 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on June 19, 2019, provided that the reporting person continues to serve as a director of the issuer through such date. Read SEC document |
| May 21, 2018 Filed May 23, 2018 07:35 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionNon-Employee Stock Option · Derivative | 10,000 | $0.00 Strike: $20.16 | $0.00 |
DisclosureSEC source: 0001209191-18-032493 · doc4.xml · derivative · entry 3 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2018-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised. F2 · derivative.exercise_date: The shares subject to these options vested in installments and were fully vested on 5/21/2009. Read SEC document |
| May 21, 2018 Filed May 23, 2018 07:35 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Tax withholdingCommon Stock | 8,727 | $23.10 | $201,593.70 |
DisclosureSEC source: 0001209191-18-032493 · doc4.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,273 Read SEC document |
| May 21, 2018 Filed May 23, 2018 07:35 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionCommon Stock | 10,000 | $20.16 | $201,600.00 |
DisclosureSEC source: 0001209191-18-032493 · doc4.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised. Read SEC document |
| April 16, 2018 Filed Aug 14, 2018 23:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 28 | $0.00 | $0.00 |
DisclosureSEC source: 0001325812-18-000031 · primary_doc.xml · nonDerivative · entry 3 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 2,855 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,300 | $145.41 | $189,033.00 |
DisclosureSEC source: 0001553878-18-000026 · edgardoc.xml · nonDerivative · entry 6 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,968 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 11, 2018. F7 · price: Sale prices ranged from $145.16 to $145.79 Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 9,165 | $144.67 | $1,325,900.55 |
DisclosureSEC source: 0001553878-18-000026 · edgardoc.xml · nonDerivative · entry 5 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,268 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 11, 2018. F6 · price: Sale prices ranged from $144.14 to $145.13 Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 8,644 | $143.58 | $1,241,105.52 |
DisclosureSEC source: 0001553878-18-000026 · edgardoc.xml · nonDerivative · entry 4 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,433 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 11, 2018. F5 · price: Sale prices ranged from $143.12 to $144.11 Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 9,217 | $142.68 | $1,315,081.56 |
DisclosureSEC source: 0001553878-18-000026 · edgardoc.xml · nonDerivative · entry 3 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,077 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 11, 2018. F4 · price: Sale prices ranged from $142.12 to $143.11 Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 7,250 | $141.74 | $1,027,615.00 |
DisclosureSEC source: 0001553878-18-000026 · edgardoc.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,294 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 11, 2018. F3 · price: Sale prices ranged from $141.12 to $142.10 Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,884 | $140.43 | $405,000.12 |
DisclosureSEC source: 0001553878-18-000026 · edgardoc.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,544 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 11, 2018. F2 · price: Sale prices ranged from $140.00 to $140.95 Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 22:48 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001553878-18-000009 · edgardoc.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-02-28 F1 · shares: Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2017. The reporting person also received 30,000 options to purchase shares of ALNY common stock that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to the remaining shares ratably at the end of each three-month period thereafter over the following thirty-three (33) months Read SEC document |
| January 17, 2018 Filed Aug 14, 2018 23:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 17 | $0.00 | $0.00 |
DisclosureSEC source: 0001325812-18-000031 · primary_doc.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 2,827 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 21:37 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001325812-17-000036 · edgardoc.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F1 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective December 20, 2017, the compensation committee of the Company determined the first performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 22:25 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2015 (right to buy) · Derivative | 10,000 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001553878-17-000063 · edgardoc.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective November 6, 2017, the compensation committee of the Company determined the first performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 23:45 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (Right to Buy) · Derivative | 85,316 | $0.00 Strike: $21.35 | $0.00 |
DisclosureSEC source: 0001553878-17-000054 · primary_doc.xml · derivative · entry 4 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,316 shares Expires 2018-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2017. F3 · derivative.exercise_date: The stock option vested as to 25% of the shares on the first anniversary of the grant date and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.